Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826800 · ClinicalTrials.gov registry record · NA
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT00826800: Clinical Trial NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00826800 is a NA study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00826800, a NA study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving chemo-therapy for colon cancer before surgery can shrink the cancer and lead to a higher rate of cure than operating first and then giving chemotherapy. Standard treatment for colon cancer is to first operate, and then, if the tumor is advanced, give chemotherapy for about 6 months. However, surgery delays the time until chemotherapy can start, since the body needs time to heal from the operation. During this time any cancer cells that remain in the body that were not removed by the operation may be allowed to grow. Giving chemotherapy first could attack the cancer cells right from the start, not only at the tumor site that we know of, but also at the site of any cancer cells that may have spread to other parts of the body. Another possible reason why giving chemo therapy first might work better is that the blood vessels that feed the cancer cells are intact before surgery and thus chemotherapy can travel directly to the cancer. This study will also use the drug bevacizumab, in addition to the standard chemotherapy. Bevacizumab has been on the market since 2004 for colon cancer that has spread to other organs, but its use in earlier stage colon cancer, as planned in this trial, is still under study.
Interventions
- DRUG FOLFOX and bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826800
The ClinicalTrials.gov registry entry for NCT00826800 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FOLFOX and bevacizumab is the first listed.
NCT00826800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826800 about?
NCT00826800 is a clinical study titled "Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer". The purpose of this study is to see if giving chemo-therapy for colon cancer before surgery can shrink the cancer and lead to a higher rate of cure than operating first and then giving chemotherapy. Standard treatment for colon cancer is to first operate, and then, if the tumor is advanced, give che...
What is the current status of trial NCT00826800?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2009-02. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00826800?
The interventions under investigation include: FOLFOX and bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00826800?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.